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Dyskinesia is a serious motor complication caused by prolonged administration of L-DOPA
to patients affected by Parkinson’s disease. Accumulating evidence indicates that L-DOPA-
induced dyskinesia (LID) is primarily caused by the development of sensitized dopamine
D1 receptor (D1R) transmission in the medium spiny neurons (MSNs) of the striatum.This
phenomenon, combined with chronic administration of L-DOPA, leads to persistent and
intermittent hyper-activation of the cAMP signaling cascade. Activation of cAMP signal-
ing results in increased activity of the cAMP-dependent protein kinase (PKA) and of the
dopamine- and cAMP-dependent phosphoprotein of 32 kDa (DARPP-32), which regulate
several downstream effector targets implicated in the control of the excitability of striatal
MSNs. Dyskinesia is also accompanied by augmented activity of the extracellular signal-
regulated kinases (ERK) and the mammalian target of rapamycin complex 1 (mTORC1),
which are involved in the control of transcriptional and translational efﬁciency. Pharma-
cological or genetic interventions aimed at reducing abnormal signal transduction at the
level of these various intracellular cascades have been shown to attenuate LID in different
animal models. For instance, LID is reduced in mice deﬁcient for DARPP-32, or following
inhibition of PKA. Blockade of ERK obtained genetically or using speciﬁc inhibitors is also
able to attenuate dyskinetic behavior in rodents and non-human primates. Finally, admin-
istration of rapamycin, a drug which blocks mTORC1, results in a strong reduction of LID.
This review focuses on the abnormalities in signaling affecting the D1R-expressing MSNs
and on their potential relevance for the design of novel anti-dyskinetic therapies.
Keywords: cAMP, dopamine- and cAMP-regulated phosphoprotein 32 kDa, extracellular signal-regulated protein
kinases, immediate early genes, mammalian target of rapamycin, Parkinson’s disease
The striatum, which includes the caudate–putamen and the
nucleus accumbens, is the major component of the basal ganglia,
a set of interconnected subcortical structures critically involved in
motor control. The GABAergic medium spiny neurons (MSNs)
are the principal neuronal type in the striatum and represent the
main receiving station of the basal ganglia. Their large dendritic
arborization is innervated by excitatory glutamatergic inputs from
cortical, thalamic, and limbic areas and modulatory dopaminergic
inputs from midbrain neurons located in the substantia nigra pars
compacta (SNc) and the ventral tegmental area.
In the caudate–putamen, which corresponds to the dorsal part
of the striatum, dopamine regulates the activity of MSNs by act-
ing on dopamineD1 receptors (D1Rs) and dopamineD2 receptors
(D2Rs). It has become clear that D1Rs and D2Rs have a very dis-
tinct pattern of expression in the two projection pathways which
connect the striatum to the output nuclei of the basal ganglia (i.e.,
substantia nigra pars reticulata and internal segment of the globus
pallidus). In particular, it has been shown that D1Rs are located in
the MSNs which directly innervate the substantia nigra pars retic-
ulata and the internal segment of the globus pallidus. In contrast,
D2Rs are present in the MSNs which project to these nuclei indi-
rectly, via a circuit including the external segment of the globus
pallidus and the subthalamic nucleus (Gerfen et al., 1990; Gerfen,
1992; Gong et al., 2003; Valjent et al., 2009).
The above distinction is at the basis of a commonly accepted
model of basal ganglia transmission, which proposes that the
activation of the neurons of the“direct”striatonigral pathway facil-
itatesmotor activity via disinhibition of thalamo-cortical neurons,
whereas activation of the neurons of the “indirect” striatopal-
lidal pathway reduces motor activity by increasing inhibition
on thalamo-cortical neurons (Albin et al., 1989; Alexander and
Crutcher, 1990; DeLong, 1990). The same model also posits that
dopamine promotes motor activity by increasing the activity of
striatonigral MSNs and, concomitantly, by inhibiting striatopal-
lidal MSNs (Albin et al., 1989; Gerfen et al., 1990). These con-
trasting actions of dopamine depend on the selective expression
of D1Rs and D2Rs in striatonigral and striatopallidal MSNs, as
well as on the coupling of these receptors to different G-proteins.
Thus, activation of D1Rs leads to Gαolf-mediated stimulation of
adenylyl cyclase and increased cAMP, whereas activation of D2Rs
leads to Gαi/o-mediated inhibition of adenylyl cyclase (Stoof and
Kebabian, 1981; Herve et al., 1993; Zhuang et al., 2000).
StriatalMSNs are targetedby a largenumberof drugs, including
addictive substances and antipsychotic drugs.Moreover,MSNs are
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the main target of medications used for the treatment of Parkin-
son’s disease (PD), a neurodegenerative disorder characterized
by the progressive loss of the dopaminergic neurons of the SNc
(Hornykiewicz, 1963; Braak et al., 2003). PD is commonly treated
with the dopamine precursor l-DOPA, which efﬁciently counter-
acts the motor symptoms of the disease, i.e., rigidity, tremor, and
hypokinesia (Cotzias et al., 1967; Birkmayer and Hornykiewicz,
1998). However, prolonged administration of l-DOPA results in
the appearance of choreic, dystonic, and ballistic movements, col-
lectively referred to as l-DOPA-induced dyskinesia (LID). These
involuntary movements represent a serious limitation to the cur-
rent pharmacotherapy for PD, particularly during the advanced
stages of the disease (Obeso et al., 2000; Fabbrini et al., 2007).
The need for a therapy able to efﬁciently counteract LID has
led to considerable progress in the understanding of the mole-
cular basis of this motor disorder. In particular, striatal MSNs
have become the subject of intense investigations, which identi-
ﬁed a number of molecular abnormalities implicated in dyskinetic
behavior. These abnormalities are primarily linked to the loss of
dopamine input to the basal ganglia, which strongly enhances the
responsiveness of MSNs to dopaminergic drugs. Such a sensitiza-
tion is especially evident in the case of l-DOPA, which, following
interruption of the nigrostriatal dopaminergic input, acquires the
ability to affect multiple signaling pathways. One of the main goals
of current research onLID is to study abnormal signaling processes
induced by l-DOPA in the dopamine-depleted striatum and to
determine their involvement in the emergence of pathological
motor behavior.
Accumulating evidence indicates that LID develops in response
to activation of sensitized D1Rs located on the MSNs of the
direct striatonigral pathway. The effects produced by l-DOPA in
these neurons are not limited to hyper-activation of the canonical
cAMP/dopamine- and cAMP-regulatedphosphoproteinof 32 kDa
(DARPP-32) cascade, but include modiﬁcations of signaling path-
ways not typically related to dopaminergic transmission, such as
the extracellular signal-regulated kinases (ERK) and the mam-
malian target of rapamycin (mTOR) cascades. The present review
focuses on these signaling abnormalities and on their potential
relevance for the treatment of LID.
MECHANISMS OF D1R SENSITIZATION IN PD: ALTERATIONS
IN RECEPTOR DISTRIBUTION, G-PROTEIN COUPLING, AND
ADENYLYL CYCLASE EXPRESSION
In simple terms, the development of sensitized D1R transmis-
sion in PD can be regarded as a compensatory response to
the lack of dopamine in the striatum. However, a clear under-
standing of the mechanisms implicated in this phenomenon
has been elusive. Studies using 6-hydroxydopamine (6-OHDA)
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), two
toxins used to generate experimental models of PD, indicate
that the number and afﬁnity of D1Rs is unchanged following
dopamine depletion (Breese et al., 1987; Savasta et al., 1988;
Marshall et al., 1989; Joyce, 1991; Aubert et al., 2005). Similar
results were obtained in postmortem samples from parkinsonian
patients (Pimoule et al., 1985; Shinotoh et al., 1993; Hurley et al.,
2001). However, work performed in non-human primates indi-
cates that the loss of dopaminergic input to the striatum results in
increased recruitment of D1Rs at the plasma membrane of MSNs
(Guigoni et al., 2007), a phenomenon of potential relevance for
the induction of LID.
Studies performed inMPTP lesionedmonkeys have shown that
repeated administration of l-DOPA increases the binding of the
D1R antagonist SCH23390 to striatal membranes (Aubert et al.,
2005). This effect is not accompanied by changes in the expres-
sion of D1R mRNA, suggesting that it may depend on alterations
in the number of functionally available receptors. In support of
this possibility, it has been shown that, in rodent and non-human
primate models, LID is associated with increased localization of
D1Rs at the cell surface,whichmay be caused by impaired receptor
internalization and trafﬁcking (Guigoni et al., 2007; Berthet et al.,
2009).
The pathological enhancement in the number of D1Rs at
the plasma membrane is likely to contribute to the increase in
D1R transmission associated to LID and represents a poten-
tial target for therapeutic interventions. In line with this idea,
recent ﬁndings have shown that LID is reduced by promoting
G-protein coupled receptor (GPCR) desensitization. This process
starts with the phosphorylation of the receptor by GPCR kinases
(GRKs), followed by binding to arrestins and receptor internal-
ization (Shenoy and Lefkowitz, 2003). Experiments performed in
6-OHDA-lesioned rats and MPTP lesioned monkeys show that
lentiviral-mediated overexpression of the GRK6 in the striatum
attenuates LID (Ahmed et al., 2010). In contrast, dyskinesia is
worsened when GRK6 expression is reduced by transfection with a
GRK6 miRNA. Moreover,GRK6 overexpression does not interfere
with the anti-akinetic action of l-DOPA and may therefore rep-
resent a potential strategy to control dyskinetic behavior (Ahmed
et al., 2010).
In cortical neurons, activation of the transcription factor cAMP
response element-binding protein (CREB) is known to increase
the levels of brain-derived neurotrophic factor (BDNF), which
is involved in activity-dependent synaptic plasticity (Shieh et al.,
1998; Tao et al., 1998). Interestingly, repeated administration
of l-DOPA promotes BDNF expression in the frontal cortex
of 6-OHDA-lesioned rats, via activation of dopamine D1-type
receptors (Guillin et al., 2001). This effect, in concomitance with
6-OHDA-induced overexpression of BDNF TrκB receptors, is
thought to increase the levels of dopamine D3 receptors (D3Rs) in
the striatum (Guillin et al., 2001). EnhancedD3R expression in the
MSNsof thedirect pathway is associated toLID (Bordet et al., 1997,
2000; Guillin et al., 2001; Bezard et al., 2003) and may play a role
in this condition by further exacerbating sensitized D1R transmis-
sion. In fact, D3Rs have been shown to exert a synergistic effect on
D1R-mediated transmission through direct intramembrane inter-
action (Fiorentini et al., 2008; Marcellino et al., 2008). In support
of this possibility, co-treatment with l-DOPA and the D3R antag-
onist ST 198 restores normal levels of membrane-bound D1Rs in
dyskinetic animals (Berthet et al., 2009) and counteracts dyskine-
sia in experimental models of PD (Bezard et al., 2003; Kumar et al.,
2009; Visanji et al., 2009; but see also Mela et al., 2010).
The increased recruitment of D1Rs at the plasma membrane
may also be responsible for the increase in coupling of striatal
D1Rs to Gαolf protein, which has been described in the striata
of dyskinetic monkeys (Aubert et al., 2005). In connection to
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this observation, studies performed in 6-OHDA-lesioned rats
and in postmortem samples from parkinsonian patients have
demonstrated that loss of striatal dopamine is accompanied by
increased levels of Gαolf (Herve et al., 1993; Corvol et al., 2004;
Rangel-Barajas et al., 2011). However, Gαolf overexpression sub-
sides during chronic l-DOPA administration (Corvol et al., 2004;
Rangel-Barajas et al., 2011) and striatal levels of Gαolf in dyski-
netic mice are similar to those of control animals (Rangel-Barajas
et al., 2011).
Striatal MSNs express high levels of adenylyl cyclase type 5
(Glatt and Snyder, 1993; Mons and Cooper, 1994), which is stim-
ulated in response to D1R-mediated activation of Gαolf (Herve
et al., 1993; Zhuang et al., 2000). Evidence obtained using 6-
OHDA-lesioned rats shows that dopamine depletion increases the
levels of adenylyl cyclase type 5 in the striatum (Rangel-Barajas
et al., 2011). A similar increase is also observed in the substantia
nigra pars reticulata,which is innervated by the MSNs of the direct
pathway (cf. above; Rangel-Barajas et al., 2011). Interestingly, these
effects aremaintained during repeated administration of l-DOPA,
but only in animals displaying severe dyskinesia (Rangel-Barajas
et al., 2011).
In summary, the work described above indicates that LID is
associated to increased recruitment of D1Rs at the cell surface and
to overexpression of adenylyl cyclase type 5 in the striatal MSNs
of the direct pathway (Figure 1). These modiﬁcations are likely
to inﬂuence dopaminergic transmission in the striatum and may
underlie the enhancement in the ability of l-DOPA to increase the
levels of cAMP, thereby activating cAMP-dependent protein kinase
(PKA). The importance of augmented PKA activity in dyskinesia
is indicated by the observation that, in 6-OHDA-lesioned rats,
striatal infusion of the PKA inhibitor Rp-cAMPS attenuates LID
(Lebel et al., 2010). The following sections will focus on the effects
produced by l-DOPA-induced activation of the cAMP/PKA cas-
cade and on their potential relevance for the development and
expression of LID.
DOWNSTREAM OF cAMP AND PKA: ROLE OF DARPP-32 IN
DYSKINESIA AND ABNORMAL CORTICOSTRIATAL
DEPOTENTIATION
Dopamine D1 receptor-mediated transmission in striatal MSNs
depends not only on PKA-dependent phosphorylation of down-
stream target proteins, but also on concomitant reduction of their
dephosphorylation. This parallel mechanism is based on the abil-
ity of PKA to phosphorylate and activate DARPP-32, a potent
inhibitor of protein phosphatase 1 (PP-1). Inhibition of PP-1 sup-
presses the dephosphorylation of several downstream targets of
PKA, thereby amplifying behavioral responses produced by acti-
vation of cAMP signaling (Fienberg et al., 1998; Greengard, 2001;
Borgkvist and Fisone, 2007).
The sensitization of D1Rs produced by dopamine depletion
is reﬂected by the large increase in DARPP-32 phosphoryla-
tion observed in response to the administration of L-DOPA.
In rodent models of PD l-DOPA-induced activation of the
cAMP/PKA/DARPP-32 cascade has been associated to the emer-
gence of dyskinesia (Picconi et al., 2003; Santini et al., 2007; Lebel
et al., 2010). In MPTP lesioned non-human primates, increased
phosphorylation of DARPP-32 has been shown to persist for up
FIGURE 1 | Schematic diagram illustrating some of the major
abnormalities related to sensitized D1R-signaling and associated to
LID. In PD, the loss of striatal dopamine leads to sensitization of D1Rs on
the striatonigral MSNs of the direct pathway. Emerging evidence indicates
that, if persistent, this phenomenon results in the appearance of dyskinesia.
D1R sensitization may be caused by augmented D1R expression at the cell
surface. Chronic administration of L-DOPA promotes the release of BDNF
from corticostriatal neurons, leading to activation of TrκB receptors and
increased expression of D3Rs, speciﬁcally in striatonigral MSNs. Direct
interaction with D3Rs is likely to increase the levels of membrane-bound
D1Rs, thereby exacerbating D1R sensitization and dyskinetic behavior. In
line with this possibility, D3R antagonists have been found to counteract
LID in experimental models of PD. Sensitized D1R transmission may also
be caused by increased levels of adenylyl cyclase 5 (AC 5) in striatonigral
MSNs. Increased responsiveness of the D1R/Gαolf/AC5 machinery to
L-DOPA results in augmented synthesis of cAMP and hyper-activation of
PKA and DARPP-32. Pharmacological inhibition of PKA, or genetic
inactivation of DARPP-32 have been shown to reduce LID. Abnormal
PKA/DARPP-32 signaling increases the phosphorylation of GluR1. This
effect promotes the excitability of MSNs and may participate in the loss of
corticostriatal LTD and depotentiation associated to LID. Sensitized
D1R-mediated transmission leads also to activation of ERK, which controls
transcriptional and translational processes. Both pharmacological and
genetic suppression of ERK signaling counteracts the development and
expression of LID. In the nucleus, PKA/DARPP-32 and ERK/MSK1 signaling
leads to phosphorylation of CREB and histone H3, and increased expression
of immediate early genes and prodynorphin. Reduced expression/activity of
ΔfosB efﬁciently counteracts LID. Activation of ERK promotes
mTORC1-dependent signaling, thereby accelerating mRNA translation.
Blockade of mTORC1 with rapamycin has been found to attenuate the
development of LID. Red color indicates receptors or signaling components
whose targeting reduces LID. See text for abbreviations.
to 3months of l-DOPA chronic administration, suggesting that
DARPP-32 is involved not only in the development, but also in the
maintenance and expression of LID (Santini et al., 2010a).
Genetic inactivation of DARPP-32 has proven to be an effective
strategy to reduce experimental LID. Following 6-OHDA lesion
and repeated administration of l-DOPA, DARPP-32 knock out
mice display signiﬁcantly less dyskinetic behavior in comparison
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to wild type littermates (Santini et al., 2007). Interestingly, LID
is also reduced by cell-speciﬁc inactivation of DARPP-32 in the
MSNs of the direct pathway. In contrast, selective inactivation of
DARPP-32 in indirect MSNs does not affect the ability of l-DOPA
to induce abnormal involuntary movements (Bateup et al., 2010).
Taken together, these studies indicate not only the importance of
PKA-induced activation of DARPP-32 in dyskinesia, but also the
primary role played in this condition by theD1R-expressingMSNs
of the direct pathway.
The abnormal activation of PKA and the concomitant hyper-
phosphorylation of DARPP-32 observed in experimental models
of LID lead to changes in the state of phosphorylation of target
effector proteins, which may have profound repercussion on the
excitability of striatal MSNs (Figure 1). High-frequency stimula-
tion is known to induce long-term potentiation (LTP) at corti-
costriatal synapses (Calabresi et al., 1992b). Dopamine depletion
abolishes LTP, which is rescued by systemic administration of l-
DOPA (Centonze et al., 1999; Picconi et al., 2003, 2008). Once
established,LTPcanbe reversedby low frequency stimulation (Pic-
coni et al., 2003, 2008). This phenomenon, called depotentiation,
is blocked by inhibition of PP-1 and,most importantly, is absent at
the corticostriatal synapses of dyskinetic rats (Picconi et al., 2003,
2008). It has been proposed that depotentiation may prevent the
generation of aberrant motor patterns, such as dyskinesia, by eras-
ing non-essential information and normalizing striatal synaptic
efﬁciency (Picconi et al., 2003, 2008; Calabresi et al., 2010). Thus,
dyskinesia may be caused by l-DOPA through stimulation of sen-
sitized D1Rs, hyper-activation of PKA, increased phosphorylation
of DARPP-32, inhibition of PP-1, and abolishment of corticostri-
atal depotentiation (Picconi et al., 2003; Calabresi et al., 2010).
One possible mechanism by which inhibition of PP-1 by
DARPP-32 may prevent depotentiation involves changes in the
state of phosphorylation of the GluR1 subunit of the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate
receptor. Dyskinetic behavior correlates with the ability of l-
DOPA to increase PKA-dependent phosphorylation of GluR1 at
Ser845 (Santini et al., 2007). This effect is strictly dependent on
concomitant phosphorylation of DARPP-32, since it is abolished
in DARPP-32 knock out mice (Santini et al., 2007). Phosphory-
lation of GluR1 at Ser845 promotes glutamatergic transmission
(Banke et al., 2000; Mangiavacchi and Wolf, 2004) and may par-
ticipate in the block of depotentiation observed in dyskinetic rats
(Picconi et al., 2003). Increased glutamatergic transmission may
also be produced by augmented synaptic recruitment of AMPA
receptor GluR2/3 subunits, which has been described in the stri-
ata of dyskinetic monkeys (Silverdale et al., 2010). The idea of the
involvement in dyskinesia of enhanced AMPA receptor transmis-
sion is further supported by the observation that, in non-human
primates, LID is increased by an AMPA receptor agonist and
reduced by anAMPA receptor antagonist (Konitsiotis et al., 2000).
cGMP AND LOSS OF LONG-TERM DEPRESSION IN
DYSKINESIA
In the rat, depletion of striatal dopamine results in the loss of
corticostriatal long-term depression (LTD). This effect is counter-
acted by D1R and D2R agonists, exogenous dopamine, or l-DOPA
(Calabresi et al., 1992a; Picconi et al., 2008, 2011). Interestingly,
recent evidence indicates that in dyskinesia the loss of LTD pro-
duced by 6-OHDA persists even after chronic l-DOPA admin-
istration (Picconi et al., 2011). This phenomenon, together with
the loss of depotentiation (Picconi et al., 2003), is in line with the
idea that LID is caused by impaired control of striatal excitatory
transmission.
The lack of corticostriatal LTD associated with LID may be due
to the decrease in cGMP signaling observed in dyskinetic animals
(Giorgi et al., 2008). In the striatum, LTD depends on a group
of interneurons, which express nitric oxide synthase (Kawaguchi
et al., 1995; Calabresi et al., 1999). Nitric oxide activates a sol-
uble form of guanylyl cyclase highly expressed in MSNs (Ding
et al., 2004), leading to increased synthesis of cGMP and activa-
tion of cGMP-dependent protein kinase. Notably, cGMP signaling
is implicated in LTD, which can be induced pharmacologically
with zaprinast and UK-343664, two inhibitors of cGMP phospho-
diesterase (the enzyme responsible for the conversion of cGMP
to GMP; Calabresi et al., 1999; Picconi et al., 2011). Interestingly,
local injection of these drugs in the striatum of dyskinetic rats has
been found to rescue LTD and to reduce the dyskinetic response
(Picconi et al., 2011). Further studies will be necessary to under-
stand the molecular basis of the persistent loss of LTD associated
to dyskinetic behavior.
ENHANCED ERK SIGNALING IN DYSKINESIA
The changes in synaptic plasticity associated to LID, such as loss
of depotentiation and LTD are likely to occur also in response
to modiﬁcations in the activity of signaling pathways involved
in the control of gene expression. ERK regulate transcriptional
and translational processes (Thomas and Huganir, 2004; Costa-
Mattioli et al., 2009) and have been implicated in the induction
of striatal LTP (Xie et al., 2009). In neuronal cells, ERK sig-
naling is promoted via Ca2+-dependent activation of the brain
speciﬁc exchange factor Ras-guanyl nucleotide releasing factor
1 (Ras-GRF1, or CDC25Mm; Martegani et al., 1992; Shou et al.,
1992). Ras-GRF1 induces the exchange of GDP for GTP on the
small G-protein Ras (Farnsworth et al., 1995). A similar effect is
produced by the calcium- and diacylglycerol-regulated guanine
nucleotide exchange factor II (CalDAG-GEF II), which is highly
enriched in striatal MSNs (Toki et al., 2001). Ras-GTP, in turn,
activates the protein kinase Raf, leading to the phosphorylation of
the mitogen-activated protein kinase/ERK kinase (MEK) and ERK
(Figure 2).
It has been shown that substances that promote D1R transmis-
sion, such as cocaine and amphetamine, phosphorylate ERK via
activation of the PKA/DARPP-32 signaling cascade. This effect is
involved in the development of the locomotor sensitization pro-
duced by repeated administration of these drugs (Valjent et al.,
2005). This ﬁnding suggests that changes in ERK phosphory-
lation may also be implicated in LID, which, in experimental
models, develops in concomitance with a marked sensitization
of the locomotor effect (i.e., turning behavior) produced by l-
DOPA (Carey, 1991). Studies performed in 6-OHDA-lesioned rats
show that depletion of striatal dopamine confers to a D1R ago-
nist the ability to increase the phosphorylation of ERK (Gerfen
et al., 2002). Similarly, l-DOPA, which is inactive when injected in
naive or sham-lesioned animals, induces a large increase in ERK
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FIGURE 2 |Targeting signaling upstream and downstream of ERK in
LID.The abnormal activation of ERK produced by administration of L-DOPA
in experimental models of PD is implicated in the emergence of dyskinetic
behavior. ERK is activated by Ras-GRF1 and CalDAG-GEF II, which induce
the exchange of GDP for GTP on the small G-protein Ras. Ras-GTP activates
the protein kinase Raf, leading to the phosphorylation of MEK and ERK.
Dyskinesia is attenuated in Ras-GRF1 knock out mice. A similar reduction is
produced by inhibition of Ras, or MEK, achieved using lovastatin and SL327,
respectively. ERK activation promotes the expression of the transcription
factor ΔFosB, which is also implicated in LID. In addition, dyskinesia is
associated to ERK-dependent activation of mTORC1, which is likely to
accelerate local protein synthesis. Blockade of mTORC1 signaling with
rapamycin has been found to reduce LID. See text for abbreviations.
phosphorylationwhen administered to 6-OHDA-lesionedmice or
MPTP intoxicated monkeys (Pavon et al., 2006; Santini et al., 2007,
2009a, 2010a).
The mechanism underlying this change in efﬁcacy is likely to
depend on sensitized D1R-mediated transmission and abnormal
activation of cAMP signaling. Thus, blockade of PKA prevents the
ability of l-DOPA to increase ERK phosphorylation in 6-OHDA-
lesioned rats (Lebel et al., 2010). Moreover, in the dorsal striatum,
the ability of l-DOPA to activate ERK appears to be attenuated by
genetic inactivation of DARPP-32 (Santini et al., 2007). However,
this last observation has been recently challenged (Gerfen et al.,
2008) and further work will be necessary to assess the involve-
ment of DARPP-32 in l-DOPA-induced ERK phosphorylation,
particularly within the dorsolateral striatum.
The existence of a causal link between ERK and dyskinesia was
ﬁrst provided in a mouse model of LID. In particular, it was shown
that blockade of ERK phosphorylation with SL327, an inhibitor
of MEK, reduced the development of dyskinesia (Santini et al.,
2007). Subsequent studies showed that lovastatin, which reduces
Ras isoprenylation and activity (Mendola and Backer, 1990; Sebti
et al., 1991), attenuates dyskinesia induced by l-DOPA in the 6-
OHDA-lesioned rat (Schuster et al., 2008). In the same model, it
was found that LID is associated to increased striatal expression
of CalDAG-GEF II, which may represent a further mechanism
accounting for increased ERK activation (Crittenden et al., 2009;
cf. above; Figure 2).
The involvement in LID of the Ras–ERK pathway is further
supported by recent evidence indicating that dyskinesia is attenu-
ated in Ras-GRF1 knock out mice (Fasano et al., 2010; Figure 2).
Moreover, in MPTP intoxicated monkeys, viral vector-mediated
inhibition of Ras-GRF1 reverses pre-established LID (Fasano et al.,
2010). This observation suggests that ERK signaling is involved
not only in the development of LID but also in its expres-
sion/maintenance. It should be noted, however, that the phospho-
rylation of ERK produced by l-DOPA in the dopamine-depleted
striatum appears to subside over prolonged drug administration.
Thus, in dyskinetic MPTP lesioned monkeys, l-DOPA loses its
ability to promote ERK phosphorylation following 3months of
chronic treatment (Santini et al., 2010a).
A similar phenomenon has been recently described in mice
deﬁcient for the transcription factor Pitx3 (Ding et al., 2011).
These animals lack the dopaminergic innervation to the stria-
tum and display akinesia reminiscent of parkinsonism (van den
Munckhof et al., 2003; Hwang et al., 2005). In Ptix3 knock
out mice, acute l-DOPA increases the number of phospho-
ERK-positive MSNs. However, this effect disappears following
7weeks of daily administration, in concomitance with the appear-
ance of increased phospho-ERK immunoreactivity in cholinergic
interneurons (Ding et al., 2011). The progressive reduction in
the ability of l-DOPA to activate ERK in striatal MSNs was also
observed in 6-OHDA-lesioned mice, further supporting the idea
of a partial normalization in ERK signaling occurring over pro-
longed periods of drug administration (Ding et al., 2011). The
increase in phospho-ERK observed in cholinergic neurons is difﬁ-
cult to appreciate using western immunoblotting, since these cells
represent only about 2% of striatal neurons (Zhou et al., 2002).
Nevertheless, in the striatum, cholinergic interneurons give rise to
a particularly dense arborization and to a large number of synap-
tic contacts (Bolam et al., 1984; Phelps et al., 1985; Contant et al.,
1996). Thus, augmented ERK signaling and increased activity in
this speciﬁc neuronal population may have profound repercus-
sions on striatal MSNs (Ding et al., 2011). In line with this idea,
administration of the muscarinic acetylcholine receptor antago-
nist, dicyclomine, reduces dyskinetic behavior in Ptix3 knock out
and 6-OHDA-lesioned mice (Ding et al., 2011).
SEARCHING FOR MECHANISMS OF DYSKINESIA
DOWNSTREAM OF ERK
Taken together the studies described above indicate that LID can
be counteracted by reducing the activity of the Ras–ERK cascade
through pharmacological inhibition of Ras (Schuster et al., 2008)
and MEK (Santini et al., 2007). However, this approach is likely to
produce negative side-effects, due to the involvement of ERK in
basic physiological processes, ranging from synaptic plasticity to
cell survival (Orban et al., 1999; Thomas and Huganir, 2004; Kim
and Choi, 2010). This limitation can be at least in part resolved by
acting on Ras-GRF1, which is speciﬁcally expressed in neuronal
cells and is not implicated in cell survival (Fasano et al., 2010).
Alternatively, negative side-effects can be reduced by narrowing
the speciﬁcity of intervention through acting downstream of ERK.
This approach is particularly interesting, since ERK is involved in
the control of a large number of target effector proteins, both in
the nucleus and in the cytoplasm (Yoon and Seger, 2006; Figure 1).
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The mitogen- and stress-activated protein kinase 1 (MSK1) is
an important component of the ERK signaling cascade, speciﬁcally
localized in the nucleus (Deak et al., 1998). LID is accompanied
by a large increase in the phosphorylation of MSK1, which occurs
selectively in the D1R-expressing neurons of the direct pathway
(Santini et al., 2007, 2009a). In MSNs, activation of MSK1 leads
to phosphorylation of CREB (Brami-Cherrier et al., 2005), which
regulates the expression of genes involved in synaptic plasticity
and drug addiction (Carlezon et al., 2005; Figure 1). Prolonged
administration of l-DOPAhas been found to increaseCREBphos-
phorylation in a large proportion of striatal neurons. This effect
is mimicked by a D1R agonist and is prevented by inhibition of
PKA (Oh et al., 2003), which is known to regulate CREB. In cul-
tured striatal neurons, PKA-dependent phosphorylation of CREB
is blocked by inhibition of ERK (Zanassi et al., 2001). Moreover,
the ability of cocaine to increase CREB phosphorylation in striatal
MSNs is prevented by administration of SL327 (Brami-Cherrier
et al., 2005). Therefore, it is likely that the increase in CREB phos-
phorylation induced in the striatum by repeated administration of
l-DOPA is producedby concomitant activationof cAMP/PKAand
ERK/MSK1 signaling. The potential implication of altered CREB
phosphorylation in LID remains to be fully evaluated, particu-
larly in view of the observation that striatal infusion of antisense
oligonucleotide against CREB exacerbates the dyskinetic response
to l-DOPA, rather than reducing it (Andersson et al., 2001).
Administration of l-DOPA to 6-OHDA-lesioned rodents
results in a large increase in the state of phosphorylation of his-
toneH3 at Ser10 (Santini et al., 2007, 2009a;Darmopil et al., 2009),
which is known to depend on activation of MSK1 (Davie, 2003;
Figure 1). This effect occurs in theMSNs of the direct pathway and
correlates with the severity of dyskineticmovements (Santini et al.,
2007, 2009a; Darmopil et al., 2009). Increased phosphorylation on
Ser10 of histone H3 is thought to mediate transcriptional activa-
tion (Nowak and Corces, 2004) and may participate in changes in
gene expression associated to LID.
ERK-DEPENDENT CHANGES IN GENE EXPRESSION
ASSOCIATED TO DYSKINESIA
Evidence obtained in rodent and non-human primate models
indicates that LID is accompanied by increased levels of stable iso-
forms ofΔFosB (Andersson et al., 1999; Pavon et al., 2006; Berton
et al., 2009; Darmopil et al., 2009; Fasano et al., 2010), a truncated
splice variant of the immediate early gene fosB (Nestler et al.,
2001; Figures 1 and 2). Importantly, increased ΔFosB has also
been observed in postmortem striatal samples from parkinsonian
patients treated with l-DOPA (Tekumalla et al., 2001).ΔFosB acts
as a transcriptional activator by forming heterodimers with JunD,
which bind to the activator protein-1 site of several late response
genes. Enhanced expression of ΔFosB has been implicated in
the long-term effects produced by substances of abuse, including
dopaminergic drugs such as cocaine (Nestler et al., 2001).
The increase in ΔFosB associated to LID is restricted to the
D1R-expressing MSNs of the direct pathway (Andersson et al.,
1999; Pavon et al., 2006) and is mediated via activation of the
D1R/cAMP cascade. Thus, genetic inactivation of D1Rs, or stri-
atal infusion of Rp-cAMPS prevent the ability of l-DOPA to
increase ΔFosB (Darmopil et al., 2009; Lebel et al., 2010). The
accumulation of ΔFosB requires also PKA-catalyzed phosphory-
lation of DARPP-32 (Zachariou et al., 2006), which is strongly
induced by administration of l-DOPA (Santini et al., 2007). ERK
signaling is also involved in the regulation of ΔFosB, since inac-
tivation of Ras-GRF1 (Fasano et al., 2010), or pharmacological
inhibition of Ras (Schuster et al., 2008), abolish the increase in
ΔFosB expression induced by l-DOPA.
Several lines of evidence indicate that the up-regulation of
ΔFosB produced by chronic administration of l-DOPA partic-
ipates in the development of dyskinesia. Studies performed in
6-OHDA-lesioned rats showed that LID is reduced by striatal
injection of a fosB antisense oligonucleotide (Andersson et al.,
1999; Figure 2). In the same model, it has been recently shown
that viral vector-induced overexpression of ΔFosB enhances the
ability of l-DOPA to induce dyskinetic behavior (Cao et al.,
2010). Furthermore, experiments in MPTP lesioned macaques
showed that overexpression ofΔJunD, a truncated variant of JunD
lacking a transactivation domain and acting as a dominant neg-
ative inhibitor of ΔFosB, reduces dyskinesia (Berton et al., 2009;
Figure 2).
Previous studies showed that repeated administration of a
D1R agonist to 6-OHDA-lesioned rats increases the expression of
mRNA coding for the opioid peptide prodynorphin in the MSNs
of the direct pathway (Gerfen et al., 1990). A similar regulation
was later found to correlate with dyskinesia and to depend on
l-DOPA-induced expression of ΔFosB (Andersson et al., 1999;
Figure 1). Although increased prodynorphin is regarded as a very
robust marker of LID, a clear understanding of the role played by
enhanced opioid transmission in dyskinesia is complicated by con-
trasting data obtained using opioid receptor antagonists (Samadi
et al., 2006). Further studies will be necessary to fully characterize
the signiﬁcance of this and other effects dependent on ΔFosB for
the development and expression of LID.
Another immediate early gene whose expression is increased
in dyskinesia is that coding for the transcription factor Zif268
(or NGFI-A/Krox24/Egr1). Acute administration of l-DOPA to 6-
OHDA-lesioned rats increases zif268 mRNA in both striatopallidal
and striatonigral MSNs. Interestingly, repeated l-DOPA adminis-
tration leading to dyskinesia normalizes the levels of zif268 mRNA
in striatopallidal neurons, but not in striatonigral neurons (Carta
et al., 2005). The lack of normalization of zif268 expression in the
MSNs of the direct pathwaymay be due to the persistent activation
of ERK observed in these cells in association with LID (Darmopil
et al., 2009; Santini et al., 2009a). Indeed, ERK is required for
cocaine-induced increase in zif268 expression (Valjent et al., 2006).
Interestingly, Zif268 is involved in the sensitized motor response
produced by repeated administration of cocaine (Valjent et al.,
2006), suggesting that activation of the ERK/Zif268 cascade may
represent a common mechanism implicated in abnormal motor
behaviors (Figure 1).
In the hippocampus, Zif268 is required for the late phase of
LTP (Jones et al., 2001). This regulation is thought to depend on
the ability of Zif268 to induce Arc (or Arg3.1; Li et al., 2005),
another immediate early gene involved in multiple forms of neu-
ronal plasticity, including LTP and LTD (Bramham et al., 2008).
Interestingly, increased expression of Arc has been found in the
striata of dyskinetic rats, speciﬁcally at the level of the MSNs of
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the direct pathway (Sgambato-Faure et al., 2005). These observa-
tions raise the possibility that activation of the ERK/Zif268/Arc
signaling pathway may participate in the plastic changes associ-
ated to LID. In particular, abnormal increase of Zif268 and Arc
may promote or exacerbate LTP, leading to the loss of corticostri-
atal depotentiation associated to dyskinesia (Picconi et al., 2003;
Figure 1).
ERK-DEPENDENT REGULATION OF MAMMALIAN TARGET OF
RAPAMYCIN COMPLEX 1
The involvement of ERK in LID may depend not only on the regu-
lation of transcription factors (i.e., CREB,ΔFosB, and Zif268), but
also on the modulation of local protein synthesis in the cytoplasm.
In this regard, the mammalian target of rapamycin complex 1
(mTORC1), a key regulator of mRNA translation (Costa-Mattioli
et al., 2009), is emerging as a particularly interesting subject of
study (Santini et al., 2010b; Figure 1).
ERK has been proposed to activate mTORC1 through several
mechanisms. For instance, ERK may promote the activation of the
small GTPase, Ras homolog enriched in brain (Rheb),which stim-
ulates mTORC1 (Long et al., 2005; Ma et al., 2005). In addition,
ERK can phosphorylate and activate the regulatory associated pro-
tein of mTOR (or Raptor), an essential component of mTORC1,
thereby promoting mTORC1-mediated signaling (Carriere et al.,
2008).
Studies performed in the hippocampus showed that activated
mTORC1 participates to the maintenance of LTP by promot-
ing local protein synthesis immediately after synaptic stimulation
(Tsokas et al., 2005). This effect, which requires activation of
ERK (Tsokas et al., 2007), may be implicated in the maladaptive
processes associated with LID,which affect the functioning of cor-
ticostriatal synapses (see above; Picconi et al., 2003, 2011;Calabresi
et al., 2010). In line with this possibility, it has been found that
administration of l-DOPA to 6-OHDA-lesioned mice promotes
the phosphorylation of the p70 ribosomal S6 kinases (S6Ks) and
the initiation factor 4E (eIF4E)-binding protein (4E-BP; Santini
et al., 2009b), two major targets of mTORC1 (Thomas et al., 1979;
Gingras et al., 2001; Ruvinsky and Meyuhas, 2006). These effects,
which lead to activation of the eIF4E and to the phosphorylation of
the ribosomal protein S6 (rpS6), are thought to accelerate protein
synthesis (Richter and Sonenberg, 2005; Ruvinsky and Meyuhas,
2006; Roux et al., 2007).
The increase in mTORC1 signaling produced by l-DOPA
occurs selectively in the MSNs of the direct pathway and requires
concomitant activation of ERK signaling (Santini et al., 2009b).
Blockade of mTORC1 does not interfere with the ability of l-
DOPA to counteract the akinetic effect of the 6-OHDA lesion, but
it diminishes the development of LID. Thus, combined adminis-
trationof l-DOPAand rapamycin,a selective allosteric inhibitor of
mTORC1 (Oshiro et al., 2004), leads to a substantial reduction in
the emergence of abnormal involuntary movements in dopamine-
depleted mice (Santini et al., 2009b; Figure 2). These results
suggest that enhanced mRNA translation, leading to abnormal
protein synthesis may participate in the development of LID. In
this regard, it will be important to identify downstream effectors
speciﬁcally affected by abnormalmTORC1 signaling (Klann,2009;
Santini et al., 2009b, 2010b).
CONCLUSION
The study of the molecular mechanisms at the basis of LID has
unveiled a number of abnormalities in signal transduction asso-
ciated to the development and manifestation of this condition
(cf. Figures 1 and 2). Most importantly, it has been shown that
drugs targeting speciﬁc intracellular components of the signaling
machinery in striatalMSNs efﬁciently counteract the emergence of
LID. These drugs include inhibitors of the Ras–ERK and mTORC1
cascades, such as SL327, lovastatin, and rapamycin (Figure 2), as
well as inhibitors of the cGMP phosphodiesterase, such as zapri-
nast and UK-343664. Although some of these substances (e.g.,
lovastatin and rapamycin) have been tested in clinical settings,
their use for the treatment of dyskinesia may present problems
related to long-term side-effects at both central and peripheral
level. This indicates the importance of testing additional sub-
stances interacting with signaling changes potentially implicated
in LID and occurring downstream of the ERK and mTORC1
cascades.
This review focused on abnormal signaling at the level of
the D1R-expressing MSNs of the direct striatonigral pathway.
Whereas acting on these neurons seems to produce beneﬁcial
effects against dyskinetic behavior, other neuronal populations
may represent equally feasible targets. For instance, pharmacolog-
ical and genetic interventions aimed at modifying transmission
in the D2R-expressing MSNs of the indirect pathway have been
shown to produce anti-dyskinetic effects (Schwarzschild et al.,
2006; Gold et al., 2007; Schuster et al., 2009). This is not sur-
prising, since both direct and indirect MSNs act in large part by
controlling the same set of structures (i.e., substantia nigra pars
reticulata and internal segment of the globus pallidus), ultimately
involved in the control exerted by the basal ganglia on motor func-
tion. Recent work indicates that other groups of striatal neurons
are also involved in LID. In particular, it has been shown that
dyskinesia may depend on changes in the activity of cholinergic
interneurons, as well as of interneurons expressing nitric oxide
synthase. One important question in the study of the mechanisms
of dyskinesia will be to identify signaling abnormalities associated
with LID and occurring at the level of these distinct neuronal pop-
ulations, to understand their impact on basal ganglia transmission
and to assess their contribution to dyskinetic behavior.
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